Core Insights - Kane Biotech Inc. has signed non-exclusive distribution and sales agreements for its revyve Antimicrobial Wound Gel product line with Patient Care Medical and Life Biologics, enhancing its market presence in the U.S. [1][2] Group 1: Distribution Agreements - The agreements with Patient Care Medical and Life Biologics will expand Kane Biotech's presence in targeted sales channels and geographic markets, with Life Biologics distributing nationally and Patient Care Medical focusing on Louisiana, Mississippi, and the Gulf Coast [2][3] - Initial shipments of the revyve product line are being prepared for the near term [2] Group 2: Company Strategy and Product Information - Expanding the U.S. distribution network is a key priority for Kane Biotech, supporting its near-term commercialization objectives [3] - Kane Biotech is focused on developing novel wound care treatments that disrupt biofilms, which contribute to antibiotic resistance in wounds, with its revyve product line addressing both biofilms and wound bacteria [3] - The revyve Antimicrobial Wound Gel and its variants are U.S. FDA 510(k) cleared and Health Canada approved, indicating regulatory compliance and market readiness [3]

Financial Performance - Total revenue for Q4 2024 was $125,859, an increase from $57,788 in Q4 2023, primarily driven by contract animal health manufacturing revenue [3] - Gross loss for Q4 2024 was $(87,204), compared to a gross profit of $34,300 in Q4 2023, with $209,775 in inventory write-downs related to the DermaKB product line [3] - Total operating expenses for Q4 2024 were $933,479, down from $1,292,635 in Q4 2023, mainly due to adjustments in short-term incentive expenses [3] - Net income for Q4 2024 was $227,321, a significant improvement from a net loss of $(1,522,425) in Q4 2023, aided by a deferred tax recovery of $1,310,256 [3] - For the full year 2024, total revenue reached $2,080,879, up from $148,980 in 2023, attributed to higher product revenue [3] - Gross profit for the year was $872,096, compared to $109,470 in 2023, with similar inventory write-downs as in Q4 [3] - Total operating expenses for 2024 were $4,795,093, an increase from $3,466,856 in 2023, driven by higher employee compensation and consulting expenses [3] - Net loss for the year was $(3,161,097), an improvement from $(4,562,345) in 2023, with the same deferred tax recovery impacting both years [3] Corporate Strategy - The company is focusing on four verticals of its coactiv+ biofilm dispersion technology-based wound care product portfolio, particularly the revyve product line in the U.S. market [2] - New activities will be undertaken with clinicians in the U.S. to enhance distribution strategies for the revyve product line [2] - Cost reduction initiatives have been implemented to lower monthly operating costs, including a reduction in overhead [6] - The company has decided to delay the clinical study of its DispersinB Acne Cleanser to 2026 [6] - The binding term sheet with FB Dermatology S.R.L. has been terminated, and the acquisition will not proceed [7] Leadership Changes - Marc Edwards is no longer with the company as President and CEO, with Dr. Robert Huizinga appointed as interim CEO [5] - Dr. Huizinga has a background in clinical development and will resign from his position as Executive Chair at the upcoming annual meeting in June 2025 [5] Funding and Investment - Two insiders have agreed to subscribe for 12 million common shares at $0.10 per share, raising net proceeds of $1.2 million through a private placement [8] - An insider has also agreed to provide an unsecured loan of $1,000,000, repayable on demand, to support the company's operations [8] - These transactions are classified as related party transactions under Multilateral Instrument 61-101, with exemptions from formal valuation and minority approval requirements [10]